The Role of Nurses in Caring for Patients Receiving Oral Targeted Therapy in the EGFR TKIs
Article Sidebar
Main Article Content
Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors are used to treat patients with non-small cell lung cancer that have mutations in the EGFR gene. These drugs are taken orally, allowing patients to self-administer them. However, the administration of these drugs requires specific guidelines and may interact with other medications, foods, or herbs, potentially leading to harmful effects or reduced treatment efficacy. Additionally, these drugs can cause side effects that, if not properly managed, may lead to complications and negatively affect the patient's quality of life. This article aims to provide knowledge on caring for patients receiving oral EGFR TKIs, including drug mechanisms, current EGFR TKIs medications, potential side effects, grading of severity, side effect management, and guidelines for patient care. In addition, the role of nurses in patient care includes assessment and education, particularly in medication management and patient self-care, as well as case studies. This knowledge aims to support nurses in applying best practices and evidence-based knowledge to optimize patient care.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Anderson, M. K., Bettencourt, E. V., & LeFebvre, K. B. (2024). Defining the role and responsibilities of the oral
anticancer Medication Nurse Navigator. Seminars in Oncology Nursing, 40(2), 151582.
Arnold-Korzeniowski, K. (2023). Gefitinib (Iressa®). Retrieved from https://www.oncolink.org/cancer-
treatment/oncolink-rx/gefitinib-iressa-r.
AstraZeneca, (2024), About TAGRISSO for late-stage EGFR+ NSCLC. Retrieved from https://www.tagrisso.com/late-
stage-egfr-nsclc/about-tagrisso.html.
Aw, D. C. W., Tan, E. H., Chin, T. M., Lim, H. L., Lee, H. Y., & Soo, R. A. (2018). Management of epidermal growth
factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia-Pacific Journal
of Clinical Oncology, 14(1), 23–31.
Bettencourt, E. (2014). Oral chemotherapy—what your patients need to know. Oncology Issues, 29(6), 44–51.
Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, ... Nicolson, M. (2015). Expert
consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK. Drugs, 75(12), 1335–1348.
Carrington, C. (2015). Oral targeted therapy for cancer. Australian Prescriber, 38(5), 171.
Chen, J. Y., Liang, S. K., Chuang, T. Y., Chu, C. Y., Tu, C. H., Yeh, Y. J., ...Chen, K. Y. (2024). The impact of
comorbidities, neutrophil-to-lymphocyte ratio, and drug toxicities on quality of life in lung cancer patients
receiving EGFR-TKI therapy. Journal of the Formosan Medical Association, 123(2), 198–207.
Cury-Martins, J., Eris, A. P. M., Abdalla, C. M. Z., Silva, G. de B., Moura, V. P. T. de, & Sanches, J. A. (2020).
Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.
Anais Brasileiros de Dermatologia, 95(2), 221–237.
Du, X., Liu, W., Chen, K., Wang, Z., Li, X., Yang, L., …Xie, X. (2022). Impact of the Gastric Acid Suppressant Use on
the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis. Frontiers in
Pharmacology, 13, 796538.
Gay, C., Toulet, D., & Le Corre, P. (2017). Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus
on cytochrome P450, transporters, and acid suppression therapy. Hematological Oncology, 35(3), 259–280.
Haddad, R., Guigay, J., Keilholz, U., Clement, P. M., Fayette, J., de Souza Viana, L., … Gauler, T. (2019). Afatinib as
second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck:
Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and
Neck 1 trial. Oral Oncology, 97, 82–91.
Hofheinz, R. D., Segaert, S., Safont, M. J., Demonty, G., & Prenen, H. (2017). Management of adverse events during
treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Critical Reviews in Oncology/Hematology, 114, 102–113.
Huynh Dagher, S., Blom, A., Chabanol, H., & Funck-Brentano, E. (2021). Cutaneous toxicities from targeted therapies
used in oncology: Literature review of clinical presentation and management. International Journal of
Women’s Dermatology, 7(5), 615–624.
Karachaliou, N., Fernandez-Bruno, M., Bracht, J. W. P., & Rosell, R. (2019). EGFR first- and second-generation TKIs—
there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research, 8(Suppl 1),
S23–S47.
Kucharczuk, C. R., Ganetsky, A., & Vozniak, J. M. (2018). Drug-drug interactions, safety, and pharmacokinetics of
EGFR tyrosine kinase inhibitors for the treatment of non–small cell lung cancer. Journal of the Advanced
Practitioner in Oncology, 9(2), 189.
Li, Q., Liu, Z., Kolli, S., Wetz, K., Griffith, N., & Poi, M. J. (2016). Stability of extemporaneous erlotinib, lapatinib, and
imatinib oral suspensions. American Journal of Health-System Pharmacy: AJHP: Official Journal of the
American Society of Health-System Pharmacists, 73(17), 1331–1337.
Maher, H. M., Alzoman, N. Z., Shehata, S. M., & Abahussain, A. O. (2017). UPLC-ESI-MS/MS study of the effect of
Green tea extract on the oral bioavailability of erlotinib and lapatinib in rats: Potential risk of pharmacokinetic
interaction. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences,
–1050, 30–40.
Melosky, B., & Hirsh, V. (2014). Management of common toxicities in metastatic NSCLC related to anti-lung cancer
therapies with EGFR-TKIs. Frontiers in Oncology, 4, 238.
Multinational association of supportive care in cancer. (2016). MASCC Oral Agent Teaching Tool (MOATT). Retrieved
from https://mascc.org/resources/assessment-tools/mascc-oral-agent-teaching-tool-moatt/
Occhipinti, M., Brambilla, M., Galli, G., Manglaviti, S., Giammaruco, M., Prelaj, A., … Marchetti, P. (2021). Evaluation
of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-
kinase inhibitors. Journal of Personalized Medicine, 11(5).
Otten, L.-S., Heine, R. ter, Chiong, J., Martin, J., van den Heuvel, M. M., Piet, B., & Burger, D. (2022). EP08.02-090
sotorasib drug-drug Interactions: essential guidance requested by physicians worldwide. Journal of Thoracic
Oncology, 17(9), S444–S445.
Peters, S., Zimmermann, S., & Adjei, A. A. (2014). Oral epidermal growth factor receptor tyrosine kinase inhibitors for
the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions. Cancer
Treatment Reviews, 40(8), 917–926.
Phillips, W. J., Leighl, N. B., Blais, N., & Wheatley, P. (2024). Oral targeted therapy for the treatment of non–small cell
lung carcinoma. CMAJ, 196(16), E558–E561.
Pluzanski, A., & Piorek, A. (2016). Side effects of tyrosine kinase inhibitors — management guidelines. Oncology in
Clinical Practice, 12(4), 113–118.
Siegel, R. D., LeFebvre, K. B., Temin, S., Evers, A., Barbarotta, L., Bowman, R. M., …Olsen, M. M. (2024).
Antineoplastic therapy administration safety standards for adult and pediatric oncology: ASCO-ONS standards.
Sohn, H. S., Kim, H., Song, I. S., Lim, E., Kwon, M., Ha, J. H., ...Kwon, J. W. (2015). Evidence supporting the need for
considering the effects of smoking on drug disposition and effectiveness in medication practices: a systematic
narrative review. International Journal of Clinical Pharmacology and Therapeutics, 53(8), 621–634.
Thomas, K. S., Billingsley, A., Amarshi, N., & Nair, B. A. (2010). Elevated International Normalized Ratio associated
with concomitant warfarin and erlotinib. American Journal of Health-System Pharmacy, 67(17), 1426–1429. Veerman, G. D. M., Hussaarts, K. G. A. M., Jansman, F. G. A., Koolen, S. W. L., van Leeuwen, R. W. F., & Mathijssen,
R. H. J. (2020). Clinical implications of food-drug interactions with small-molecule kinase inhibitors. The
Lancet. Oncology, 21(5), e265–e279.
Zhang, H. (2016). Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to
evolutionize the therapy of lung cancer. Drug Design, Development and Therapy, 10, 3867.
